anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To provide new antibiotic substances Mer-NF8054A and X useful as an antimycotic agent and producible by culturing a microbial strain belonging to the genus Aspergillus and capable of producing the antibiotic substance Mer-NF8054A or X and collecting the product from the cultured product. CONSTITUTION:A microbial strain belonging to the genus Aspergillus and capable of producing an antibiotic substance Mer-NF8054A or antibiotic substance Mer-NF8054X [e.g. Aspergillus ustus Mer-NF8054a (FERM P-13236)] is inoculated on a medium and cultured at 28 deg.C for 88hr under aeration and agitation. The cultured liquid is separated into microbial cells and supernatant by filtration and the obtained cells are extracted with methanol. The extracted liquid is concentrated, diluted with water, extracted with ethyl acetate and concentrated to dryness. The obtained solid is dissolved in chloroform and purified by column chromatography to obtain the antimycotic antibiotic substance Mer-NF8054A and Mer-NF8054X expressed by formula (X is CH2 or CO).
Disclosed are peptides having a capacity of detecting hepatitis C antivirus antibodies (VHC) in the serum of infected individuals, having the general formula: R1-aa1-aa2-aa3-aa4-aa5-aa6-aa7-aa8-aa9-aa10-aa11-aa12-aa13-aa14-aa15-R2 wherein if R1 is H and R2 is OH, then the formula represents a pentadecapeptide where the N-terminal and C-terminal aminoacids are respectively aa1 and aa15; if R1 and R2 are polypeptide chains of 15 aminoacids represented by the above formula, which may be similar to each other or different, and repeated n times, the formula represents homopolymers or heteropolymers. aa4 is Ser or Arg; aa5 is Arg, Pro or Lys; aa6 is Gly, Gln or Thr; aa7 is Asn, Asp or Lys; aa10 is Ser, Phe or Thr; aa11 is Pro or Asn; aa12 is Thr, Gly ou Arg; and aa1, aa2, aa3, aa8, aa13, aa14 and aa15 are each any one of the 20 possible natural aminoacids. Also disclosed are methods for the synthesis of said peptides. The peptides and the polymers may be used individually or in combinations in order to detect through ELISA assays or other types of immunological assays the presence of anti-VHC antibodies in the serum of infected persons. These peptides can also be used associated to a resin or to a macromolecule (BSA, trunks of lysines, etc.) providing for the 'presentation' for an ELISA assay or for flow cytofluorometry. These peptides may also be used to induce antibodies for the detection of the virus of hepatitis C, or its fragments, in human or animal biological liquids or tissues.
The invention relates to a traditional Chinese medicine for treating haemorrhoids. Haemorrhoids are soft intravenous boluses formed by expansion and flexion of venous plexus under the mucosa of the tail end of the human rectums and under the anal canal skin. Haemorrhoids are commonly seen in people groups who stand frequently and who sit for a long time, especially, the office workers. Haemorrhoids comprise internal hemorrhoid, external hemorrhoid and mixed hemorrhoid, and belong to a chronic disease having one or more soft intravenous boluses formed by varix of venous plexus on the bottom of the anus rectum and on the anal mucosa. When a person continuously exerts large force when defecating, the intravenous pressure at the part rises up repeatedly, and the vein swells. Many fat people also can suffer from haemorrhoids. If people suffer from haemorrhoids, the swelling and twisted venous wall in the anus can become very thin, and can be easily broken when the people defecate.
Participants (n=107) will be asked to continue with usual care/routine and complete survey measures at each time point. Participants will be provided with access to the intervention after their study participation.
Mycophenolate mofetil USP has demonstrated teratogenic effects in rats and rabbits (see Pregnancy and WARNINGS:Embryofetal Toxicity). Mycophenolate mofetil tablets USP should not be crushed and mycophenolate mofetil capsules USP should not be opened or crushed. Avoid inhalation or direct contact with skin or mucous membranes of the powder contained in mycophenolate mofetil capsules USP and mycophenolate mofetil oral suspension (before or after constitution). If such contact occurs, wash thoroughly with soap and water; rinse eyes with plain water. Should a spill occur, wipe up using paper towels wetted with water to remove spilled powder or suspension. Caution should be exercised in the handling and preparation of solutions of mycophenolate mofetil intravenous. Avoid direct contact of the prepared solution of mycophenolate mofetil intravenous with skin or mucous membranes. If such contact occurs, wash thoroughly with soap and water; rinse eyes with plain water.
The invention discloses a lily Qingkailing preparation and a preparation method thereof, relating to a medical preparation containing raw materials. The lily Qingkailing preparation which takes lily as the main materias and takes gardenia, honeysuckle, white granulated sugar and dextrine as accessories and the preparation method thereof are provided. The raw material components and the contents thereof according to percents by weight are as below: 9-12 percent of lily, 8-10 percent of gardenia, 9-15 percent of honeysuckle and 4-6 percent of dextrine, and the rest is white granulated sugar powder. The preparation method comprises the following steps: the lily, the gardenia and the honeysuckle are boiled for two times with water, the filtrate liquor are merged and filtered to obtain filtrate ; the filtrate is concentrated to form clear paste; ethanol is added in the clear paste and is filtered to obtain paste after standing; the ethanol is recycled; and the paste obtained by filtering and the dextrine are added in the white granulated sugar powder, then evenly mixed and dried to obtain the product. The lily Qingkailing preparation is accessory food which has the functions of fever reduction, detoxification, moistening lung, nerve calming, and the like. The invention has the advantages of simple production technology and no pollution.
Patients with hereditary angioedema (HAE), suffer from recurring and mostly unforeseeable attacks of acute oedema of subcutaneous tissues of various organs. The pathophysiological correlate of this disease is a deficiency in functionally active C1-Esterase Inhibitor (C1-INH). Today, two main types of HAE are described. In HAE type I, an impaired synthesis and an elevated turnover of a normal and functional active C1-INH molecule takes place, causing reduced amounts in functionally active C1-INH. In HAE type II, normal levels of a functionally impaired C1-INH molecule are synthesized. Both defects are inherited as an autosomal dominant trait. HAE type III is limited to females and not associated with C1-INH deficiency; the pathophysiology of this type remains to be determined. Corticosteroids, antihistamines or epinephrine usually do not exert any positive effect in acute attacks caused by HAE. This is of particular importance as these types of medication are often used in case of oedema in general. In case of acute oedema in patients suffering from HAE, the intravenous administration of C1-INH concentrate (e.g., Berinert P) is the treatment of choice. The study is performed to investigate the s.c. versus i.v. administration of Berinert P in patients with hereditary angioedema (HAE) to establish a second administration mode in cases where i.v. access is not suitable.
<P>PROBLEM TO BE SOLVED: To obtain a pharmaceutical composition that even an elderly person having difficulty in swallowing easily takes and masks bitterness of amlodipine besilate.  <P>SOLUTION: The pharmaceutical composition is obtained by coating amlodipine besilate alone or a mixture of amlodipine besilate and an excipient with a coating agent containing one or more selected from the group consisting of a water-insoluble polymer, an enteric polymer and a gastrosoluble polymer. The amount of the coating agent is 0.5-1.5 pts.wt. based on 1 pt.wt. of amlodipine besilate.  <P>COPYRIGHT: (C)2008,JPO&INPIT
BACKGROUND: Vestibular migraine (VM) and Menière's disease (MD) are two common causes of recurrent spontaneous vertigo. Using history, video-nystagmography and audiovestibular tests, we developed machine learning models to separate these two disorders.
METHODS: We recruited patients with VM or MD from a neurology outpatient facility. One hundred features from six "feature subsets": history, acute video-nystagmography and four laboratory tests (video head impulse test, vestibular-evoked myogenic potentials, caloric testing and audiogram) were used. We applied ten machine learning algorithms to develop classification models. Modelling was performed using three "tiers" of data availability to simulate three clinical settings. "Tier 1" used all available data to simulate the neuro-otology clinic, "Tier 2" used only history, audiogram and caloric test data, representing the general neurology clinic, and "Tier 3" used history alone as occurs in primary care. Model performance was evaluated using tenfold cross-validation.
RESULTS: Data from 160 patients with VM and 114 with MD were used for model development. All models effectively separated the two disorders for all three tiers, with accuracies of 85.77-97.81%. The best performing algorithms (AdaBoost and Random Forest) yielded accuracies of 97.81% (95% CI 95.24-99.60), 94.53% (91.09-99.52%) and 92.34% (92.28-96.76%) for tiers 1, 2 and 3. The best feature subset combination was history, acute video-nystagmography, video head impulse test and caloric testing, and the best single feature subset was history.
CONCLUSIONS: Machine learning models can accurately differentiate between VM and MD and are promising tools to assist diagnosis by medical practitioners with diverse levels of expertise and resources.
Mitochondria are the major sink for oxygen in the cell, consuming it during ATP production. Therefore, when environmental oxygen levels drop in the tumor, significant adaptation is required. Mitochondrial activity is also a major producer of biosynthetic precursors and a regulator of cellular oxidative and reductive balance. Because of the complex biochemistry, mitochondrial adaptation to hypoxia occurs through multiple mechanisms and has significant impact on other cellular processes such as macromolecule synthesis and gene regulation. In tumor hypoxia, mitochondria shift their location in the cell and accelerate the fission and quality control pathways. Hypoxic mitochondria also undergo significant changes to fundamental metabolic pathways of carbon metabolism and electron transport. These metabolic changes further impact the nuclear epigenome because mitochondrial metabolites are used as enzymatic substrates for modifying chromatin. This coordinated response delivers physiological flexibility and increased tumor cell robustness during the environmental stress of low oxygen.
Study subjects will be asked to take Sulodexide twice a day. The Sulodexide will be taken in addition to the regular medications the subject is on. There will be no change in these other medications. The subject will also be asked to have blood tests each month to follow kidney function. The frequency of these tests is the normal/standard frequency for persons with MPGN II/DDD and is neither increased nor decreased because of participation in this study. The study will occur over 6 months for each subject.
The invention discloses a recombinant miR-218, wherein the sequence of the recombinant miR-218 is shown in SEQ ID NO: 1 or a sequence similar to SEQ ID NO: 1 with a sequence similarity of more than 90%. In addition, the invention also discloses a production method of the recombinant miR-218 and an application of the recombinant miR-218 in hair regeneration. The invention adopts tRNA as a bracket, is embedded with a miR-218 sequence, and expresses recombinant miR-218 in escherichia coli. The recombinant miR-218 prepared by the invention is externally sprayed on the back of a unhaired C57BL/6 mouse. The results prove that the recombinant miR-218 can remarkably promote hair regeneration. The recombinant miR-218 prepared by the invention is obtained by a bioengineering technology, and has the advantages of high biological activity, convenient equipment, fast production, high yield, low cost, good functionality and the like.
Prodn. of a pharmaceutical comprises removing the mucus-like protective layer (A) from the surface of fish. Also new is an appts. for the process. More specifically, the outermost mucosal layer (the beaker layer) is removed from live fish which have been lightly stunned before being treated. USE/ADVANTAGE - (A) is useful in veterinary and human medicine to treat virus diseases, cancer and multiple sclerosis with almost no side effects. It is admin. subcutaneously (pref.) or orally (formulated with glucose to improve resorption and taste). The material must be used within 30 min. of its recovery from the fish. The subcutaneous dose is 0.5-10 ml, typically 0.5-1 ml initially, then increased gradually.
HMZ 2.0 will be delivered by a registered dietitian in weekly didactic, one-on-one discussions in remote synchronous format (e.g., Zoom). If a subject has internet connectivity issues, she will be able to participate in the remote sessions from an onsite location (e.g., laboratory space on the Penn State University Park campus, clinical space at Hershey campus or Geisinger). All intervention women will receive the baseline intervention delivered as a maximum of 24 weekly modules (depending on gestational age at enrollment) which includes: Education and Counseling (GWG/PA/EI/sedentary behaviors/sleep behaviors/stress management, etc.), Goal-Setting and Action Plans (guided and self-selected PA/EI goals including recipe and workout booklet use), Self-Monitoring (wearing/using mHealth tools to monitor GWG/PA/EI/sleep), and Featured Evidence and Fetal Growth Facts (evidence-based studies and baby growth fun facts shared with women about how mom's health impacts her baby).
FIELD: medicine. SUBSTANCE: method involves effect of ultrasonic oscillation on drugs at frequency 44.0-1600 kHz, intensity - 0.02-1.0 W/cm 2 , for 1-8 min. Under this regime elements exert microresonance of atomic-molecular structure of an aqueous solution. Oscillations can be emitted at impulse regime. Device consists of generator and emitter of ultrasonic oscillations. Emitter is made as a hollow-space cylinder or conic equipment exhibiting oscillation frequency 44.0 kHz - 1.6 mHz and intensity 0.02-1.0 W/cm 2 . The use of indicated regimes provides increase of specific activity of drugs and elimination of allergenic property. EFFECT: decreased allergenic property, enhanced effectiveness. 4 cl, 6 dwg
The present invention relates to the field of a medicinal preparation, particularly to a soft capsule composition. The soft capsule composition comprises zinc gluconate, ibuprofen and chlorpheniramine maleate which are active components. The present invention is characterized in that the composition is composed of the following materials (by weight ratio): 1 wt. % of the active components, 0.8 to 3.0 wt. % of disperse mediums, 0.02 to 0.3 wt. % of surface-active agents and 0.01 to 1.0 wt. % of suspending agents. The soft capsule composition of the present invention has the advantages of dispersed and uniform medicine and stable quality.
Patients receive astatine At 211 anti-CD45 monoclonal antibody BC8-B10 IV on any day between days -10 and -7, fludarabine IV on days -6 to -2, cyclophosphamide IV over 1 hour on days -6 to -5 and 3 to 4, and thymoglobulin IV over 4-6 hours on days -4 to -2. Patients undergo TBI on day -1 and hematopoietic cell transplant on day 0. Beginning day 5, patients also receive mycophenolate mofetil PO or IV thrice daily every 8 hours up to day 35 if no GVHD present and sirolimus PO daily until day 365. Patients undergo blood sample collection and may undergo bone marrow aspiration throughout the study.
A drug dispensing control system and a drug dispensing unit are disclosed. The drug dispensing control system includes a prescription filling system and a drug dispensing unit. The drug dispensing unit is configured to interface with the prescription filling system. The drug dispensing unit includes a canister configured to receive a prescribed amount of medication from the prescription filling system. The canister includes a single dose dispensing mechanism. The drug dispensing unit also includes circuitry configured to allow access to a dose of the medication at a predetermined interval. In certain aspects, the drug dispensing unit is approximately handheld-sized.
All subjects will receive a full physical examination at IND to determine study eligibility. Written informed consent will be obtained prior to any study procedures. The screening procedures will include: review of medical and psychiatric history, review of medications, physical examination including height and body weight, vital sign measurements, review of inclusion/exclusion criteria, clinical laboratory testing (serum chemistries, CBC, urinalysis, urinary drug screen), urine pregnancy test for females of childbearing potential and electrocardiogram in preparation for the imaging study.

Part A: Four healthy subjects will each receive one injection of 123-I INER. Serial whole body planar imaging in the anterior and posterior projection will be performed over the 8-9 hour period following injection of 5 mCi of 123-I INER and again at 18-24 hours following injection. Venous blood data will be acquired at each imaging time point. In addition a 24 hour urine collection will commence following radiotracer injection. Whole body and source organs uptake will be analyzed on anterior and posterior images for calculating the radiation absorbed doses to organs. Plasma and urine metabolites will be characterized and safety assessments obtained. Serial safety assessments will include vital signs, serum chemistries, CBC, urinalysis, and EKGs.

Part B: Six healthy subjects will each receive one injection of 123-I INER. Following bolus intravenous injection of 5 mCi of 123-I INER over 15 seconds, serial dynamic SPECT brain acquisitions will be obtained to evaluate the regional brain uptake and washout of activity. Venous blood measures will be obtained with each acquisition and characterization of 123-I INER and metabolites will be assessed. Safety assessments will include vital signs, serum chemistries, CBC, urinalysis, and EKGs.
Chronic low back pain (CLBP) is one of the most common causes of disease-related disabilities with regard to work ability, physical activity, and mobility, as well as in the development of depressive disorders and cognitive impairments. The multimodal pain therapy (MPT) is a multidisciplinary offer of medical, psychlogical and physiotherapeutic treatment. Currently, MPT is the best therapeutic option. However, there are still many non-responders. It is unknown, which patients will benefit from MPT and which contents are the most effective. Besides somatic factors, the relevance of psychosocial risk factors, such as dysfunctional pain management or disstress and depression, are evident in patients suffering from CLBP. Concepts, such as the Avoidance-Endurance Model of pain (AEM) describe different pattern with regard of mood and pain management, offering an individual therapy. Patients with a fear-avoidance response pattern (FAR) and physical inactivity as well as patients with a depressive endurance response pattern (DER) and physical overactiviity show a poorer response to therapeutical and rehabilitative treatments. On the other side, patients with an adaptive response pattern (AR) and moderate physical activity, and patients with an eustress endurance response pattern (EER) react positive to MPT. If the relevance of these pattern will be shown in patients with CLBP, this would stand for a more individualised therapy concerning psychological and physiotherapeutical treatment (e.g., ExposureTherapy, Pacing). Currently it is unknown which factors are relevant for recovery in patients with AR. One possible protective factor is the personality factor "resilience". The current research situation in the field of chronic pain and resilience is still in its early days and raises the question, if partial aspects such as a high degree of pain acceptance, of self-compassion, and a positive body image show more directly and more clearly relations to a positive response to treatment. Furthermore, research has focused on cross-sectional studies. However, only prospective longitudinal studies will provide insight in cause-and-effect-relationship. On a clinically applied basis the diagnosis of risk and protective factors will play an outstanding role to establish a more individualised therapy and rehabilitation, as also the MPT.

For the diagnosis of the different pain pattern postulated by the AEM, the 9-item Avoidance Endurance Fast-Screen (AEFS) is a reliable and valid short screening. However, it has been investigated in patients with acute pain, so far. A separate validation for patients with CLPB is necessary. Our working group wants to tie up the planned prospective study to preliminary work and show for the first time processes of patients with CLBP undergoing MPT.

On a theoretical basis results will be informative about possible protective factors being important for recovery. On a clinically applied basis we plan the validation of a short-screening of psychosocial risk- and protective factors in patients with CLBP undergoing MPT.
Paclitaxel (80 mg/m² weekly, infusion) is applicated for 12 weeks, followed by epirubicin and cyclophosphamide, applicated 4 cycles 3-weekly . In case of HER2-positive tumor patients receive tarstuzumab and pertuzumab 3-weekly during all cycles.
Infectious sporadic abortions in cattle are mainly caused by opportunistic bacteria and fungi usually present in environmental or gastrointestinal and reproductive microbiota of healthy animals. A retrospective analysis was carried out to evaluate the main opportunistic microorganisms involved in bovine abortions recorded at INTA Balcarce (Argentina) from 1997 to 2023, accounting for 2.2% of the total diagnosed etiologies of bovine abortion. The opportunistic agents identified as the cause of abortion in 29 fetuses were bacteria (90%) and fungi (10%). Escherichia coli (n = 8), Trueperella pyogenes (n = 5), and Histophilus somni (n = 4) were the bacterial species most often identified as causing infectious abortions, whereas Aspergillus spp. (n = 3) was implicated in all fungal abortions identified. Pure culture of bacteria or fungus was achieved from abomasal content and/or lung essential. Main microscopic findings were bronchopneumonia, myo- and epicarditis, meningitis, and portal hepatitis. Herein, we highlight the importance of detecting potential infectious bacteria in cultures to improve etiological diagnosis of bovine abortions associated with compatible microscopic findings to confirm the etiology.
FIELD: medicine, homeopathy, pharmacy. SUBSTANCE: invention relates to a medicinal agent comprising activated form of monoclonal, polyclonal or natural antibodies raised to cholecystokinin used in small or supersmall doses prepared by multiple successive dilution and by external effect being carried out by homeopathic technology. Invention relates also to method of treatment of functions of hepatobiliary system by modification of effects of endogenous cholecystokinin that involves the use of activated forms of antibodies raised to cholecystokinin taken in small and supersmall doses prepared by successive dilution and by external effect being preferably in different but preferable hundredth homeopathic dilutions of indicated antibodies. Invention provides the development of effective, safety agent used for treatment of damages of hepatobiliary system function and no causing the formation of tolerance. Invention can be used for treatment of damages of function of hepatobiliary system of different etiology. EFFECT: improved method and enhanced effectiveness of treatment. 3 cl, 5 tbl, 5 ex